Theriva Biologics, Inc. insider trading

Every open-market purchase and sale by Theriva Biologics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Theriva Biologics, Inc.’s insiders pay?

From October 31, 2012 to June 7, 2023, 5 insiders reported 12 open-market purchases and 3 sales not made under a pre-set plan in Theriva Biologics, Inc.

Theriva Biologics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Shallcross Steven A	CEO and CFO	8	—	—	0	—	June 7, 2023
Intrexon Corp	10% owner	1	—	—	1	—	April 3, 2019
Kanzer Steve H	10% owner	0	—	—	2	—	May 2, 2014
Kirk Randal J	10% owner	2	—	—	0	—	September 4, 2015
Ballantyne Charles Evan	Chief Financial Officer	1	—	—	0	—	May 27, 2014

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Theriva Biologics, Inc. · Funds · Politicians